Submodule
Standardized Measurement and Diagnosis
Blood pressure is a variable signal. Preparation, device validation, cuff size, posture, arm position, repetition, and measurement setting determine whether the average is clinically trustworthy.
- Patient preparation
- Validated upper-arm cuff
- Repeated averages
- White-coat and masked hypertension
Remove predictable measurement bias
Correct bladder and arm position
Average across occasions or home data
Detect white-coat and masked patterns
Prepare before measuring
The patient should rest quietly with back supported, feet flat, legs uncrossed, arm supported near heart level, and no conversation. Recent caffeine, nicotine, exercise, pain, a full bladder, or emotional distress can shift the reading and should be documented or avoided when possible.
Use a validated device and correct cuff
An automated, validated upper-arm device with a cuff bladder appropriate for arm circumference is preferred. A cuff that is too small can overestimate pressure. Wrist devices require careful positioning, and cuffless watches should not be relied on for clinical decisions until accuracy is established.
Average repeated readings
A diagnosis should generally use repeated readings across occasions or a structured home or ambulatory protocol. The first reading may be higher. Record systolic and diastolic averages rather than selecting the most favorable or alarming value.
Find white-coat and masked patterns
White-coat hypertension has elevated office but lower outside-office pressure. Masked hypertension is the reverse and can be missed by clinic readings. Home or ambulatory monitoring helps distinguish these patterns and assess treatment response.
Quick check
Submodule
Classification, Cardiovascular Risk, and Treatment Targets
The 2025 United States framework retains standard blood pressure categories and adds PREVENT-based risk to primary-prevention medication decisions.
- Blood pressure categories
- PREVENT risk
- Clinical cardiovascular disease and CKD
- Goal below 130/80 with individual considerations
Normal, elevated, stage 1, stage 2
PREVENT adds primary-prevention context
Individual considerations still matter
Goal is not safe if perfusion fails
Classify from the average
Normal is below 120 systolic and below 80 diastolic. Elevated is 120 to 129 systolic with diastolic below 80. Stage 1 is 130 to 139 systolic or 80 to 89 diastolic. Stage 2 begins at 140 systolic or 90 diastolic.
Start treatment by pressure and risk
Medication plus lifestyle is recommended for average pressure at least 140 over 90 and for selected adults at least 130 over 80 with clinical cardiovascular disease, prior stroke, diabetes, CKD, or PREVENT ten-year cardiovascular risk at least 7.5 percent.
Use lifestyle first when lower risk allows
For lower-risk stage 1 hypertension, a three- to six-month lifestyle trial can precede medication when clinically appropriate. Persistent average pressure at least 130 over 80 after that interval supports medication initiation under the 2025 framework.
Treat toward protection and tolerance
The overarching adult goal is below 130 over 80, with additional considerations for institutional care, limited predicted lifespan, pregnancy, orthostasis, and treatment burden. A target is unsafe if it produces syncope, ischemia, kidney hypoperfusion, or unacceptable adverse effects.
Quick check
Submodule
Lifestyle Therapy as a Measurable Prescription
Nutrition, sodium, potassium, activity, weight, alcohol, sleep, stress, and structural access all influence blood pressure and medication response.
- DASH-like dietary pattern
- Sodium and potassium
- Physical activity and weight
- Alcohol, sleep, stress, and access
Food quality, fiber, and minerals
Response varies with baseline intake
Progress gradually and sustain
Address stress and structural barriers
Build a heart-healthy eating pattern
A DASH-like pattern emphasizes vegetables, fruits, whole grains, legumes, nuts, and appropriate low-fat dairy while limiting excess sodium, refined foods, and saturated fat. Adapt the pattern to culture, food access, kidney function, diabetes, and patient preference.
Reduce sodium and individualize potassium
Lowering excess sodium supports pressure control, especially in salt-sensitive states. Dietary potassium can help many adults but can be dangerous with advanced kidney disease, hyperkalemia, or potassium-raising medicines. Salt substitutes require explicit review.
Prescribe sustainable activity
Regular aerobic activity, supplemented by resistance work and reduced sedentary time, can lower pressure and total risk. Start from ability and symptoms. Chest pain, syncope, severe uncontrolled pressure, or unstable disease requires clinician assessment before progression.
Address the environment around behavior
Weight, alcohol, sleep apnea, stress, tobacco exposure, medications, work schedules, neighborhood safety, and food access affect pressure. Team care and community resources make lifestyle treatment more realistic than advice detached from context.
Quick check
Submodule
First-Line Antihypertensive Medicines
Thiazide-like diuretics, ACE inhibitors or ARBs, and long-acting dihydropyridine calcium-channel blockers form the central first-line pathways, with product and comorbidity-specific selection.
- Thiazide-like diuretics
- ACE inhibitors and ARBs
- Dihydropyridine CCBs
- Class-specific monitoring
Sodium, potassium, urate, glucose
Potassium, creatinine, pregnancy
Edema, headache, gingiva
Product, dose, access, and monitoring
Use thiazide-like therapy with electrolyte awareness
Chlorthalidone, indapamide, and hydrochlorothiazide inhibit distal NCC but differ in duration and evidence. Monitor sodium, potassium, magnesium, kidney function, uric acid when relevant, glucose context, volume symptoms, lithium, and NSAID exposure.
Use one RAAS blocker, not dual blockade
ACE inhibitors reduce angiotensin II formation and bradykinin breakdown, while ARBs block AT1 receptors. Both can raise potassium and creatinine and cause hypotension. ACE inhibitors can cause cough and angioedema. Avoid ACE inhibitor, ARB, and direct renin inhibitor combinations in CKD.
Use long-acting dihydropyridine calcium-channel blockers
Amlodipine and related agents reduce arteriolar resistance. Edema reflects precapillary dilation rather than total-body sodium excess and may not respond well to a loop diuretic. Headache, flushing, gingival overgrowth, and interaction profiles vary by product.
Do not treat beta blockers as universal first line
Beta blockers are appropriate when another indication such as selected coronary disease, heart failure, or rate control is present, but they are not interchangeable and are not the default uncomplicated first-line class. Selection must follow the exact comorbidity and product evidence.
Quick check
Submodule
Combination Therapy and Comorbidity Selection
Stage 2 hypertension often benefits from two complementary first-line medicines, preferably in one pill, while albuminuric CKD, coronary disease, heart failure, pregnancy, and arrhythmia change selection.
- Single-pill combination
- Complementary mechanisms
- Albuminuric CKD
- Cardiac and pregnancy contexts
Single-pill combination preferred
Different pathways and adverse effects
No dual RAAS blockade in CKD
Evidence changes the preferred product
Start two agents in stage 2
The 2025 guideline prefers two first-line agents from different classes in a single-pill combination for adults with stage 2 hypertension. Complementary mechanisms reduce therapeutic inertia and pill burden, but baseline pressure, symptoms, frailty, and comorbidity still shape the start.
Pair mechanisms thoughtfully
An ACE inhibitor or ARB can pair with a dihydropyridine calcium-channel blocker or thiazide-like diuretic. The combination often improves efficacy and can offset selected adverse effects. ACE inhibitor plus ARB or direct renin inhibitor is not complementary safety.
Use albuminuria to guide RAAS selection
In CKD with albuminuria, an ACE inhibitor or ARB has a kidney-protective role under current kidney guidance when tolerated. Monitor creatinine and potassium after initiation or titration and during intercurrent illness. Avoid interpreting every modest creatinine rise as automatic treatment failure.
Respect disease-specific products and pregnancy
Heart failure, coronary disease, arrhythmia, aortic disease, and pregnancy can make other agents appropriate or contraindicated. RAAS blockers can harm fetal development and should not be used in pregnancy. Pregnancy management follows dedicated obstetric guidance.
Quick check
Submodule
Home Monitoring, Adherence, and Team-Based Control
Durable control requires accurate home averages, class-specific labs, symptom review, access, simplified regimens, and a team empowered to titrate through a shared protocol.
- Home blood pressure protocol
- Laboratory follow-up
- Adherence and access
- Pharmacist and team-based care
Average, do not chase each reading
Potassium, sodium, kidney function
Ask without blame
Titrate with shared protocol
Use structured home measurement
Use a validated upper-arm device and correct cuff. Measure after rest at consistent times, take repeated readings, record them, and calculate averages according to the care protocol. Do not chase every isolated value with unsupervised extra doses.
Schedule class-specific safety checks
ACE inhibitors, ARBs, and potassium-sparing medicines require potassium and kidney follow-up. Diuretics require sodium, potassium, magnesium, volume, and kidney review. Rate-slowing therapies require pulse, conduction, and symptom assessment.
Treat adherence as a systems problem
Cost, refill synchronization, adverse effects, health beliefs, work, food access, transportation, memory, literacy, language, depression, and regimen complexity all affect use. Simplify schedules, use combinations thoughtfully, and involve the patient in tradeoffs.
Use multidisciplinary care
Pharmacists, nurses, clinicians, dietitians, community health workers, and others can use standardized protocols, frequent feedback, home readings, and medication access support to improve control. Escalation should remain coordinated and documented.
Quick check
Module test
Check the connections.
Each attempt draws 10 questions from the complete 100 question bank.
Each attempt draws a fresh set and rearranges the answer choices.
References
Current clinical foundation.
Lecture material was synthesized with the following contemporary guidance. Verify local policy and current guidance before applying clinical information.